KBC Group
BMY.RT

KBC Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

KBC Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-118,188
Closed -$82K – 1330
2020
Q4 		$82K Hold
118,188
– – ﹤0.01% 1181
2020
Q3 		$266K Hold
118,188
– – ﹤0.01% 930
2020
Q2 		$424K Sell
118,188
-2,550
-2% -$9.2K ﹤0.01% 855
2020
Q1 		$459K Hold
120,738
– – ﹤0.01% 865
2019
Q4 		$364K Buy
+120,738
New +$314K ﹤0.01% 1182

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

KBC Group's BMY.RT Position: Q1 2021 in Review

KBC Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 118,188 shares — an estimated $82K sold.

KBC Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $459K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • KBC Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • KBC Group sold 118,188 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $82K.
  • KBC Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • KBC Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $459K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on KBC Group's 13F filing for Q1 2021, filed 26 Apr 2021.